Skip to main content

Advertisement

Table 2 Demographic, clinical, and immunological data in association with the resistance mutations in the PR gene of the HIV-1 isolates

From: Protease inhibitor associated mutations compromise the efficacy of therapy in human immunodeficiency virus – 1 (HIV-1) infected pediatric patients: a cross-sectional study

Parameters PI associated resistance mutations
  PI (+) N = 13 PI (-) N = 28
Age of study entry (Mean+/-SD, years) 10.2+/-5.2 10.6+/-2.7
Length of treatment (Mean+/-SD, years) 6.9+/-3.4 6.2+/-2.7
NNRTI therapy 9 (69.2%) 12 (42.9%)
TAMs mutations 10 (76.9%) 18 (64.3%)
3TC mutations 9 (64.2%) * 9 (32.1%)
NNRTI mutations 6 (46.1%) 12 (42.9%)
PI (secondary) 10 (76.9%) *** 15 (53.5%)
Clinical categories #   
B 6 (46.1) 12/27 (44.4%)
C 7 (53.9%) 15/27 (55.6%)
Immune categories ##   
1 (no suppression) 8 (61.5%) 16 (57.1%)
2–3 (moderate/severe) 5 (28.5%) 12 (42.9%)
PVL (n, %)   
<10,000 1 (7.7%) ** 14 (50.0%)
≥ 10,000 12 (92.3%) 14 (50.0%)
  1. Chi-square: * P < 0.02 ** P < 0.008 ***P < 0.0001
  2. # Immune categories based on age-specific CD4+ T-lymphocyte count.22,23
  3. ## B-moderately, C-severely symptomatic 22,23